TERCONAZOLE Drug Patent Profile
✉ Email this page to a colleague
When do Terconazole patents expire, and when can generic versions of Terconazole launch?
Terconazole is a drug marketed by Fougera Pharms, Fougera Pharms Inc, Taro, and Padagis Israel. and is included in seven NDAs.
The generic ingredient in TERCONAZOLE is terconazole. There are six drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the terconazole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Terconazole
A generic version of TERCONAZOLE was approved as terconazole by TARO on April 6th, 2004.
Summary for TERCONAZOLE
US Patents: | 0 |
Applicants: | 4 |
NDAs: | 7 |
Finished Product Suppliers / Packagers: | 7 |
Raw Ingredient (Bulk) Api Vendors: | 59 |
Clinical Trials: | 8 |
Patent Applications: | 4,768 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for TERCONAZOLE |
What excipients (inactive ingredients) are in TERCONAZOLE? | TERCONAZOLE excipients list |
DailyMed Link: | TERCONAZOLE at DailyMed |
Recent Clinical Trials for TERCONAZOLE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Hatem AbuHashim | N/A |
Assiut University | Phase 3 |
Curatek Pharmaceuticals, LLC | Phase 3 |
Pharmacology for TERCONAZOLE
Drug Class | Azole Antifungal |